Abstract 3210: A potential immunotherapeutic approach for the treatment of osteosarcoma
Marlene Hennessy(Nektar Therapeutics (United States)), Nancy P. Gordon(Kaiser Permanente), Andrew Wahba(Memorial Hermann), Souri Felix(The University of Texas MD Anderson Cancer Center), Willem W. Overwijk(Weatherford College), Takahiko Miyama(The University of Texas MD Anderson Cancer Center), Maria Gabriela Segura(Memorial Hermann), Saul Kivimäe(Nektar Therapeutics (United States)), Mariella Cabrera(Lincoln Medical Center), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 0
Related Papers
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403